

CLINICAL TRIALS TASK FORCE MEETING

MEETING MINUTES

Monday, May 22, 2006

4:30 PM – 6:00 PM

Anschutz Cancer Pavilion (ACP) Room 3263

Fitzsimons Campus

Attendees: Madeleine Kane (UCHSC), Sara Miller (CDPHE), Marjorie Bezdek (UCHSC), Jeff Thompson (UCHSC), Strode Weaver (UCHSC), and Mary Schumer (UCHSC).

AGENDA ITEM	DISCUSSION	FOLLOW UP
INTRODUCTION	<ul style="list-style-type: none">➤ The Colorado Cancer Coalition (CCC) approved the formation of this new task force approximately a year ago. The Executive Committee approved the writing of the Colorado Clinical Trials Network Proposal that Madeleine Kane and Sara Miller wrote and submitted last summer in response to the ENACT RFP. The proposal was not funded, but there is interest in this idea. (Copy of proposal distributed during the meeting).➤ The Lance Armstrong Foundation may release the ENACT RFP again and Madeleine and Sara would like to re-apply.➤ Sara gave a brief overview of the CCC structure. The CCC has a fiscal agent and she serves in an executive director role for the coalition. The CCC is not supported by state funds, and eventually it may be able to hire staff to support its functions. The Colorado Cancer Coalition is made up of one of the strongest partnerships in the country. Some state staff currently support the task forces and the coalition.➤ Some years ago, parties interested in clinical trials issues intended to take related issues to the Division of Insurance to see if they would offer support. It would be good to bring in a broad base of participation into this effort.	
OFF-LABEL DRUG USE	<ul style="list-style-type: none">➤ There are situations, such as in the cases of rare cancers, when it is appropriate to use off-label drugs that may not yet be FDA approved. Some off-label drugs may be used, but they are not likely to be put into full-blown phase 3 clinical trials.➤ The National Conference of State Legislatures (NCSL) website has information on clinical trials at http://www.ncsl.org/.➤ Through legislation or other methods, approximately 13 states require payment for	

	<p>those who participate in clinical trials. A few states have passed phase 2 coverage. Some insurance companies pay only for phase 3 treatments. States that have made progress in this area, typically had a ‘champion’ who was vocal about it.</p> <ul style="list-style-type: none"> ➤ Here in Colorado, Representative Frangas is very interested in understanding issues emerging from this task force. He is also interested in different models. Sara will put him in touch with the members of this group so he can learn more about the issues around clinical trials. 	
REPRESENTATION & COMMUNICATION	<ul style="list-style-type: none"> ➤ One of the goals of this task force is to have good statewide representation and the involvement of varied institutions in our state. ➤ The group would like to get a work plan together and once things begin moving forward, others will likely become engaged. Other members to consider: Ed Pajon, Al Cohn, Anthony Elias, Peter Raich, CCOP director, Al Marcus, Tim Byers, Lia Gore and Roger Giller from Children’s. Sara will contact Rocky Mountain Cancer Centers’ (RMCC) trials with CCOP. ➤ Methods of communication: formal sign up for task force on CCC website, access to Coalition email distribution list, will establish a page on CCC website dedicated to the Clinical Trials Task Force. 	<p>Madeleine will contact individuals from CCRP, Kaiser, Denver Health, and Rocky Mountain Cancer Centers.</p> <p>Sara will contact RMCC contact. Admin. support will work on establishing the page on the CCC website.</p>
CANCER CONFERENCE	<ul style="list-style-type: none"> ➤ The Cancer Conference will be held in Fort Collins this year at the Lory Center. The attendance is expected to be quite large this year and will include public health/oncology professionals. The group discussed the idea to have a reception meeting during this conference to discuss this task force and recruit members. It will probably be possible to get sponsorship from a pharmaceutical company such as Novartis, Roche, Bristol/Myers, or Merck. ➤ The group decided to have the next meeting/official launch & recruitment at the Cancer Conference, as the Colorectal Task Force did last year. ➤ This is an opportunity to discuss the ‘lay of the land’ and provide education about the basics of clinical trials. Marjorie talked about the Genome Institute Grant, which focuses on African American, Latino, and Native American clinical trials. This topic will be of interest to the attendees. 	<p>Mary will provide pharmaceutical contacts for Sara.</p> <p>Time will be reserved on agenda.</p>
MEETING IDEAS	<ul style="list-style-type: none"> ➤ “State of the state” on cancer clinical trials – possible presenters include Kaiser, CCOP, UCHSC, and the Rocky Mountain Cancer Centers. ➤ Panel discussion to give an update from each group moderated by Madeleine Kane or Sara Miller. Perhaps a sponsor could moderate. ➤ Open forum discussion that might set the agenda for the next year. Participants could include legislators, pharmacists, general practitioners, and oncology nurses. ➤ There is a “Clinical Trials 101” scheduled during the conference for laypersons, 	<p>Sara will request data from the Rand Study from the Lance Armstrong Foundation staff and the Millman report from C-Change.</p>

	<p>but one for medical staff may be a good idea. Perhaps, the group can lobby insurance companies, and representatives should be present at the conference.</p> <ul style="list-style-type: none"> ➤ Sara stated that a group of medical directors of insurance companies meet once per month at the Cigna building and it may be an opportunity to meet with them and discuss the task force's mission. Another forum to explore is the Small Business on Health. One of the members is an inactive CCC member. ➤ Sara is on a committee addressing comprehensive professional competencies issues for comprehensive cancer. They will be sending input to Washington, DC. 	
ACTION ITEMS		PERSON RESPONSIBLE
NEXT STEPS	<p><u>Assignments:</u></p> <ol style="list-style-type: none"> 1. Check into the possibility of having a clinical trials introduction/recruitment/reception at the cancer conference. 2. Develop a clinical trials presentation for nurses. 3. Recruit panelists for cancer conference. 4. Compile contact information of local pharmaceutical 5. Check the list of current sponsors for the conference. 6. Pull together legislative information on Phase 2 clinical trials. NCSL has this information. 7. Prepare and send out minutes from today's meeting. 8. Contact Representative Frangas and put him in touch with Jeff and Strode. They are willing to provide him with information and give him a tour. 9. Establish a CCC website page for the Clinical Trials Task Force. 	<p><u>Responsible party:</u></p> <ol style="list-style-type: none"> 1. Sara 2. Madeleine 3. Madeleine 4. Mary 5. Sara 6. Sara 7. Admin. Support 8. Sara 9. Admin. Support
Adjourn	The meeting was adjourned at 5:55 PM	
NEXT MEETING	2006 Colorado Cancer Conference	